Review: Lipid-lowering reduce cardiovascular events in type 2 diabetes

November 2004
ACP Journal Club;Nov/Dec2004, Vol. 141 Issue 3, p65
Academic Journal
The article addresses the question whether in patients with type 2 diabetes mellitus, lipid-lowering agents reduce cardiovascular disease (CVD) events. To find out the answer, randomized controlled trials (RCTs) of lipid-lowering agents that evaluated major CVD events in patients with type 2 diabetes. Studies were categorized for primary prevention (patients with no known coronary artery disease [CAD]) and secondary prevention (patients with known CAD). The article finally concludes that In patients with type 2 diabetes mellitus (with or without coronary artery disease), lipid-lowering agents reduce cardiovascular disease events.


Related Articles

  • COMMENTARY: Lipid-lowering reduce cardiovascular events in type 2 diabetes. Gami, Apoor S. // ACP Journal Club;Nov/Dec2004, Vol. 141 Issue 3, p65 

    The article presents a commentary on the study, which concluded that lipid-lowering reduce cardiovascular events in type 2 diabetes. Recent guidelines recommended lipid-lowering therapy for all patients with diabetes. However, direct evidence to support this recommendation was lacking [2]. The...

  • Aggressive lipid control fails to benefit type 2 diabetics. Campbell, Maude // Drug Topics;Jun2010, Vol. 154 Issue 6, p28 

    The article reports on the addition of fenofibrate to statin therapy can minimize cardiovascular events in patients with type 2 diabetes. It mentions that the combination lipid treatment can lower the risks of low density of lipoprotein (LDL) to patients with type 2 diabetes. According to...

  • CITATIONS AND CLINICIANS' NOTES: MANAGEMENT OF DIABETES.  // Current Medical Literature: Diabetes;2005, Vol. 22 Issue 1, p21 

    The article presents papers related to management of diabetes. The paper "Treatment Gap in the Use of Lipid-Lowering Drug Therapy in Diabetes: A Population-Based Study," by P. James, H.H. Tan and R. MacAlpine examines the use of lipid-lowering therapy compared with the presence of macrovascular...

  • A clinical study on the effect of Rishyagandha (Withania coagulans) in the management of Prameha (Type II Diabetes Mellitus). Upadhyay, B. N.; Gupta, Vandana // AYU: An International Quarterly Journal of Research in Ayurveda;Oct-Dec2011, Vol. 32 Issue 4, p507 

    The study was conducted with an objective of evaluating the role of Rishyagandha (Withania coagulans) powder in clinically diagnosed cases of Prameha. 53 Registered cases were divided into 3 groups; Group A (Rishyagandha fruits powder), Group B (Oral Hypoglycaemic Agent i.e. OHA), and Group C...

  • Multisystemic Therapy Decreases Parental Overestimation of Adolescent Responsibility for Type 1 Diabetes Management in Urban Youth. Naar-King, Sylvie; Ellis, Deborah A.; Idalski, April; Frey, Maureen A.; Cunningham, Phillippe // Families, Systems & Health: The Journal of Collaborative Family ;Jun2007, Vol. 25 Issue 2, p178 

    The goal of the present study was to determine whether multisystemic therapy (MST) could decrease parental overestimation of adolescents' responsibility for completion of diabetes care. A randomized controlled trial was conducted with 127 adolescents with type 1 diabetes and their caregivers....

  • Clinical: Diabetes and statin side-effects. Bain, Stephen // GP: General Practitioner;11/11/2005, p56 

    The article presents answers of queries on myalgia with statins and triple therapy in diabetes. Answering to a question about a patient who is taking a statin and has developed muscle pains, the author says statin-related myalgia is different from statin-related myositis or rhabdomyolysis and is...

  • Roles of Oxidants, Nitric Oxide, and Asymmetric Dimethylarginine in Endothelial Function. Siekmeier, Rüdiger; Grammer, Tanja; März, Winfried // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2008, Vol. 13 Issue 4, p279 

    The article discusses clinical studies made on the effects of reactive oxygen species (ROS), nitric oxide (NO) and asymmetric dimethylarginine (ADMA) in treating endothelial dysfunction which causes atherosclerotic vascular diseases. Studies show that the use of the mentioned agents alone cannot...

  • DIABETES DELAYS, HOSPITAL ARRIVAL, AND EMERGENCY MANAGEMENT OF ACUTE CORONARY SYNDROMES (ACS). Foo, K.; Knight, C.; Deaner, A.; J. Cooper; Ranjadayalan, K.; Suliman, A.; Timmis, A. D. // Heart;May2004 Supplement 2, Vol. 90, pA32 

    This article focuses on a diabetes delays, hospital arrival, and emergency management of acute coronary syndromes (ACS). Diabetes is a major determinant of risk in ACS. It is also associated with altered pain perception that may distort symptoms and delay diagnosis. This study has shown that...

  • An evaluation of heart rate variability and its modifying factors in children with type 1 diabetes. Özgür, Senem; Ceylan, Özben; Şenocak, Filiz; Örün, Utku A.; Doğan, Vehbi; Yılmaz, Osman; Keskin, Mahmut; Aycan, Zehra; Okutucu, Sercan; Karademir, Selmin // Cardiology in the Young;Oct2014, Vol. 24 Issue 5, p872 

    Objective: To evaluate heart rate variability by Holter monitoring in type 1 diabetic children compared with a healthy control group and determine the factors modifying heart rate variability. Methods: This was designed as a prospective study comparing 28 patients, diagnosed with type 1 diabetes...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics